Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2023-02-14 Earnings Release
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Pharnext recentre ses programmes d'études cliniques sur PXT3003, candidat médicament le plus prometteur, afin d'optimiser l'allocation de ses ressources financières
Earnings Release Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a strategic decision by Pharnext to halt the development of PXT864 for Alzheimer's disease and refocus resources on PXT3003 for CMT1A, mentioning expected Phase III results in Q4 2023. This type of announcement, detailing strategic shifts, pipeline prioritization, and management commentary, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release announcing key operational and strategic news, and not a full financial report (10-K, IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these often accompany or precede quarterly results announcements and cover strategic direction. It is not an RPA because it contains substantive strategic news, not just an announcement that a report is available. It is too detailed for a simple Regulatory Filing (RNS) and doesn't fit other specific categories like M&A (TAR) or Capital Change (CAP). Q4 2023
2023-02-14 French
Pharnext refocuses its clinical trial programs on PXT3003, its most promising drug candidate, to optimize financial resources allocation
Earnings Release Classification · 1% confidence The document is a press release dated February 14th, 2023, announcing a strategic decision by Pharnext to refocus clinical trial programs, specifically stopping development for PXT864 in Alzheimer's disease and concentrating resources on PXT3003 for CMT1A, with expected Phase III results in Q4 2023. This type of announcement, detailing strategic shifts, pipeline prioritization, and management commentary, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Dividend Notice (DIV), it best fits the 'Earnings Release' category, which covers initial announcements of key operational and financial highlights for a period or strategic update. The length (6364 chars) is substantial enough to be a full release, not just a brief RPA. Q4 2023
2023-02-14 English
Mise à disposition des documents relatifs à l'assemblée générale mixte du 24 février 2023
AGM Information Classification · 1% confidence The document title explicitly mentions 'Mise à disposition des documents relatifs à l'assemblée générale mixte du 24 février 2023' (Making available of documents relating to the mixed general meeting of February 24, 2023). It details the date, location, and key resolutions for the upcoming General Meeting, including a proposed legal restructuring (conversion to S.C.A.). This content is directly related to shareholder meetings and the materials provided in advance of them. This aligns perfectly with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. Although it is an announcement about documents being made available, the core subject matter is the AGM itself, making AGM-R a stronger fit than the general RPA or RNS, especially given the specific mention of the 'assemblée générale mixte'.
2023-02-10 French
Pharnext unveils the latest progress of the PREMIER trial, pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A
Regulatory Filings Classification · 1% confidence The document is a press release dated February 2nd, 2023, providing an update on the progress of the PREMIER trial, a pivotal Phase III clinical trial for PXT3003. It details enrollment numbers, trial phases (double-blind and open-label extension), and announces that topline results are planned for Q4 2023. This content is characteristic of an update on clinical development progress, often released to investors and the public. It is not a full financial report (10-K or IR), a transcript (CT), or a formal regulatory filing like a DVA or DIRS. Since it is an announcement detailing ongoing operational/clinical progress and future milestones, it best fits the category of a general corporate announcement or update. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release providing operational updates that don't fit the more specific categories like ER (Earnings Release) or CAP (Financing Update). However, since it is a detailed update on a clinical trial, which is core operational news for a pharma company, and it is not explicitly an earnings release, it falls under general corporate news. In the context of financial reporting databases, such clinical updates are often categorized broadly. Since it is not a formal financial report, but a news release, RNS is the best fit as a general regulatory/corporate announcement.
2023-02-02 English
Pharnext dévoile les dernières avancées de l'essai PREMIER, étude clinique pivot de Phase III de PXT3003 dans la maladie de Charcot-Marie-Tooth de type 1A
Earnings Release Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and provides an update on the progress of a clinical trial (PREMIER study for PXT3003 in CMT1A). It details patient numbers, study phases (double-blind, open-label extension), regulatory agencies (FDA, EMA), and announces the expected timing for preliminary results (Q4 2023). This format—a formal announcement of operational or clinical progress, often released to the public and investors simultaneously—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a specific operational update rather than a general regulatory notice, it aligns best with an Earnings Release (ER) which often includes key operational milestones alongside financial context (though financials are sparse here, the structure is typical of a clinical-stage biotech update released around reporting periods). Given the context of providing an update on a major clinical trial and setting expectations for future results, ER is the most appropriate fit among the options, as these updates often accompany quarterly reporting cycles. It is not a Report Publication Announcement (RPA) because it contains substantive new information about the trial status, not just an announcement that a report is available. Q1 2023
2023-02-02 French
Pharnext announces successful completion of manufacturing transfer and scale-up of PXT3003 in the United States
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific operational milestone: the successful completion of manufacturing transfer and scale-up for product PXT3003. It details progress towards potential commercialization and mentions ongoing clinical trials (PREMIER trial). This type of announcement, focusing on operational or development progress rather than routine financial results (ER, IR) or mandatory regulatory filings (10-K, DEF 14A), often falls under general corporate news or investor relations updates. Since it is not a formal financial report, a management discussion, a capital event, or a specific regulatory filing like DIRS or DIV, it best fits the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, or potentially 'Report Publication Announcement' (RPA) if it were announcing the release of a formal report, which it is not. Given the content is a specific operational update, RNS is the most appropriate fallback for non-standard, material corporate news.
2023-01-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.